{"result": "(\"entity\"<|>SOCIEDAD ESPAÑOLA DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>ORGANIZATION<|>The Sociedad Española de Endocrinología y Nutrición is an organization that published a manual on endocrinology and nutrition in Madrid in 2015.)\n##\n(\"entity\"<|>MADRID<|>GEO<|>Madrid is the capital city of Spain where the Sociedad Española de Endocrinología y Nutrición is located.)\n##\n(\"entity\"<|>ESTATINAS<|>EVENT<|>Estatinas are a class of drugs used to lower cholesterol levels and are associated with various side effects including muscle toxicity and increased risk of diabetes.)\n##\n(\"entity\"<|>FIBRATOS<|>EVENT<|>Fibratos are a class of lipid-lowering medications that can cause gastrointestinal side effects and are contraindicated in advanced liver and kidney disease.)\n##\n(\"entity\"<|>DIABETES MELLITUS TIPO 2<|>EVENT<|>Diabetes Mellitus Tipo 2 is a condition that has been associated with the use of statins, particularly in patients with pre-existing risk factors.)\n##\n(\"entity\"<|>ALCAIDE J<|>PERSON<|>Alcaide J is one of the authors of the manual on endocrinology and nutrition published by the Sociedad Española de Endocrinología y Nutrición.)\n##\n(\"entity\"<|>CARDONA F<|>PERSON<|>Cardona F is one of the authors of the manual on endocrinology and nutrition published by the Sociedad Española de Endocrinología y Nutrición.)\n##\n(\"entity\"<|>FERNÁNDEZ GARCÍA JC<|>PERSON<|>Fernández García JC is one of the authors of the manual on endocrinology and nutrition published by the Sociedad Española de Endocrinología y Nutrición.)\n##\n(\"relationship\"<|>ALCAIDE J<|>SOCIEDAD ESPAÑOLA DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>Alcaide J is an author of the manual published by the Sociedad Española de Endocrinología y Nutrición<|>7)\n##\n(\"relationship\"<|>CARDONA F<|>SOCIEDAD ESPAÑOLA DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>Cardona F is an author of the manual published by the Sociedad Española de Endocrinología y Nutrición<|>7)\n##\n(\"relationship\"<|>FERNÁNDEZ GARCÍA JC<|>SOCIEDAD ESPAÑOLA DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>Fernández García JC is an author of the manual published by the Sociedad Española de Endocrinología y Nutrición<|>7)\n##\n(\"relationship\"<|>ESTATINAS<|>DIABETES MELLITUS TIPO 2<|>The use of statins has been associated with an increased risk of developing Diabetes Mellitus Tipo 2<|>6)\n##\n(\"relationship\"<|>ESTATINAS<|>FIBRATOS<|>Statins and fibrates are both classes of lipid-lowering medications that can have interactions and side effects when used together<|>5)\n##\n(\"relationship\"<|>FIBRATOS<|>DIABETES MELLITUS TIPO 2<|>Fibrates are contraindicated in patients with advanced diabetes and can have interactions with statins<|>4)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: N | >750 | Recesiva | ↓Apo C-II |  |\n| Hiperalfalipoproteinemia | IIa | ↑ | N | Dominante poligénica | ↑Apo A-I ↓PTCE | 1/1.000 |\n\nApo: apolipoproteínas; CT: colesterol total; LDL: lipoproteína de baja intensidad; LPL: lipoproteína lipasa; N: normal; PTCE: proteína que transfiere ésteres de colesterol; TG: triglicéridos.\n\nReferencias:\n• Cardona F, Alcaide J, Fernández García JC. Manual de Endocrinología y Nutrición [Internet]. Madrid: Sociedad Española de Endocrinología y Nutrición; 2015. Capítulo 124. Epidemiología, diagnóstico y clasificación de las dislipemias; [citado 11 de noviembre de 2019]. Disponible en: https://manual.seen.es/article?id=55115050-34cc-451f-99b6-4b97ac18103c.\n\n## 28 ¿Qué asociación de fármacos hipolipemiantes se ha relacionado con un discreto aumento de las miopatías?\n\nA. Estatinas + Fibratos.\nB. Estatinas + Inhibidores de PCSK9.\nC. Estatinas + Ácido nicotínico.\nD. Estatinas + Resincolestiramina.\n\nCOMENTARIO\n\nLas estatinas, en general, son muy bien toleradas, y el porcentaje de efectos secundarios descritos en los estudios es muy bajo. Los tres efectos secundarios característicos son: toxicidad muscular, toxicidad hepática e incremento del riesgo de DM2. La toxicidad muscular con estatinas va desde las mialgias (sintomatología muscular sin elevación de la creatina cinasa (CK), con unos porcentajes muy dispares entre los estudios epidemiológicos, pero que, en general, son del 5-10%) hasta la miopatía (sintomatología muscular con elevación de CK; frecuencia < 1/1.000 pacientes), que en su grado máximo puede desencadenar una rabdomiólisis, que puede provocar insuficiencia renal aguda y muerte (extremadamente infrecuente). Hay que tener en cuenta la función renal del paciente para seleccionar la estatina más adecuada (tabla 5), así como las interacciones con determinados fármacos para limitar este efecto secundario. La toxicidad hepática se caracteriza por elevación de las enzimas hepáticas (en un 0,5-2% de los pacientes tratados), que muy raramente desemboca en fallo hepático. En general, se aconseja reducir/suspender el tratamiento con las elevaciones persistentes de las enzimas hepáticas por encima de 3 veces el límite superior de la normalidad. Un efecto secundario que cada vez está teniendo más interés en la literatura médica es el incremento del riesgo de DM2 con el tratamiento con estatinas. Este aumento del riesgo está cifrado, en algunos de los metaanálisis más importantes, en un 9%, lo que se traduce en un caso extra de diabetes por cada 255 pacientes tratados con estatinas durante 4 años, cifras ampliamente superadas por el beneficio en eventos y mortalidad cardiovascular de este tipo de fármacos. No obstante, se ha de comentar que este riesgo de incidencia de diabetes es mayor en aquellos sujetos con factores de riesgo de diabetes o con prediabetes, y con las estatinas más potentes, lo que sugiere un riesgo neutro con pravastatina o incluso una reducción de riesgo con pitavastatina.\n\nLos fibratos, por su metabolismo hepático y su excreción renal, están contraindicados en la insuficiencia hepática y renal avanzadas. Con respecto a los efectos secundarios, los más frecuentes son de la esfera gastrointestinal (dispepsia, náuseas, vómitos, diarrea) y la erupción cutánea. Los fibratos también se han asociado a un incremento de la litiasis biliar (sobre todo, clofibrato), elevaciones de las transaminasas y miopatía. Esta última, sobre todo se ha evidenciado con el uso concomitante con estatinas (en este marco, el tratamiento con fenofibrato tiene un perfil de seguridad mejor que gemfibrozilo).\n---\n# OBESIDAD, LÍPIDOS Y TRASTORNOS ELECTROLÍTICOS\n\n## Tabla 5. Dosis diarias de los fármacos hipolipemiantes más comunes en función del filtrado glomerular\n\n| FÁRMACO | FILTRADO GLOMERULAR ESTIMADO (FGe) |  |  |\n|---------|-----------------------------------|-----------------|--------------|\n|         | >60 ml/min | 60-30 ml/min | <30 ml/min |\n| Atorvastatina | 10-80 mg | 10-80 mg | 10-80 mg |\n| Fluvastatina | 20-80 mg | 20-80 mg | 20-40 mg* |\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}